Abstract | INTRODUCTION: AREAS COVERED: The aim of this review is to summarize the pharmacokinetics, and pharmacological and clinical data of 3% diquafosol tetrasodium ophthalmic solution in patients with dry eye, particularly SS. The mechanisms of impaired ocular surface due to severe dry eye, as defined by the International Dry Eye Workshop, are analyzed. EXPERT OPINION:
Diquafosol tetrasodium provides a novel mode of action in dry eye syndrome, including SS, by stimulating the quantity and quality of tear fluid secretion via various mechanisms. In clinical trials, 3% Diquafosol tetrasodium ophthalmic solution demonstrated a good safety profile and exhibited efficacy with clinical improvement of the ocular surface in dry eye including SS.
|
Authors | Dominique Bremond-Gignac, Jean-Jacques Gicquel, Frédéric Chiambaretta |
Journal | Expert opinion on drug metabolism & toxicology
(Expert Opin Drug Metab Toxicol)
Vol. 10
Issue 6
Pg. 905-13
(Jun 2014)
ISSN: 1744-7607 [Electronic] England |
PMID | 24797483
(Publication Type: Journal Article, Review)
|
Chemical References |
- Ophthalmic Solutions
- Polyphosphates
- Purinergic P2Y Receptor Agonists
- Uracil Nucleotides
- diquafosol
|
Topics |
- Humans
- Ophthalmic Solutions
- Polyphosphates
(pharmacokinetics, therapeutic use)
- Purinergic P2Y Receptor Agonists
(pharmacokinetics, therapeutic use)
- Sjogren's Syndrome
(complications, drug therapy, metabolism)
- Uracil Nucleotides
(pharmacokinetics, therapeutic use)
- Xerophthalmia
(drug therapy, etiology, metabolism)
|